Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden
Auto-generated profile, based on publicly available information
Anne Huibers
Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden
Neoadjuvant immune checkpoint inhibitors (ICIs) have been established as standard care for patients with resectable macroscopic stage III melanoma. In these patients, therapeutic lymph node dissection (TLND) has been performed. However, the PRADO trial showed that TLND and also adjuvant treatment could be omitted in patients with a major pathological response (MPR) in the index lymph node. The aim of this study was to evaluate the feasibility of using a magnetic seed (Magseed®) to localise the index node for selective removal and analysis in patients with stage III melanoma receiving neoadjuvant ICIs. Twenty consecutive patients with resectable stage III melanoma and planned TLND after neoadjuvant ICIs were included. Magseed® was placed under ultrasound guidance at start of treatment. Index lymph node (ILN) resection was performed concurrently with TLND, 6-8 weeks after treatment initiation. A handheld magnetometer (Sentimag®) was used to localise the marked lymph node. This index lymph node was analysed separately for pathological response and seed presence. Transcutaneous and intraoperative localisation was successful in all 20 patients. In 19 of 20 (95%) patients, the seed was present in the surgical specimen after resection. In one patient the Magseed® dislocated during surgery. In all eleven patients with evaluable specimen in both index lymph node metastasis and additional LN metastases, the pathological response was concordant between the index and the additional lymph nodes. In this feasibility trial evaluating Magseed® as a marker for ILN resection in patients with stage III melanoma, all marked lymph nodes were successfully localised.
23 January 2026 in European Journal of Surgical Oncology
Isolated limb perfusion (ILP) is a regional treatment for patients with melanoma in-transit metastases (ITM) confined to extremities. Reported complete response (CR) rates for ILP varies but is approximately 50-70 %. This study aims to analyze if specific immunological phenotypes could predict CR after ILP. 132 patients undergoing ILP as a first treatment for melanoma ITM between January 2012 and March 2023 were included. The number and percentage of naïve and memory T and B cell subtypes, and natural killer (NK) cells, were characterized by analyzing pre-operative blood sample using fluorescence activated cell sorting (FACS). Predictive clinical and immunological factors for CR after ILP were analysed using univariable and multivariable analysis. Response was evaluable in 119 patients (90 %), of which 53 % achieved a CR. After adjusting for age, sex, number of metastases and size of the largest metastasis, immunological factors independently associated with a CR, were percentage of cytotoxic T cells (CD3+8+) (OR 1.07, 95 % CI 1.02-1.13, p = 0.012) and percentage of naive cytotoxic T cells (CD3+8+45RA+) (OR 1.11 95 % CI 1.01-1.22, p = 0.029). Immunological phenotype described as percentage of cytotoxic T cells and naïve cytotoxic T cells are together with tumor burden important predictive factors for response after ILP for patients with melanoma ITM. This could contribute to better patient selection, individualized treatment algorithms and be a foundation for further research into systemic immunological effects of regional cancer therapies. This includes novel treatment combinations, where an ongoing trial is currently combining ILP with a PD-1 inhibitor (ClinicalTrials.gov NCT03685890).